RxDoctor Payments Data

Ali Dural, MD

Gastroenterology · Shenandoah, TXNPI 1376543470

Payments from drug & device makers

$2,613in general payments, 2019–2025

Across 55 payments — averaging $47.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Ipsen Biopharmaceuticals, Inc$278
  • Takeda Pharmaceuticals U.S.A., Inc.$166
  • Johnson & Johnson$147
  • Intercept Pharmaceuticals, Inc.$125
  • Phathom Pharmaceuticals, Inc.$125
  • plus $503 from 8 others

What the payments were for

  • Food & beverage$2,613100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,613 in reported general payments places this provider in the 40th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$255,728
Medicare patients
1,021
Services billed
1,972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab24$158,794
CreonLipase/Protease/Amylase74$118,711
XifaxanRifaximin11$44,142
Mesalamine68$37,066
LinzessLinaclotide31$34,620
ZenpepLipase/Protease/Amylase14$22,139
MotegrityPrucalopride Succinate11$9,641
MovantikNaloxegol Oxalate17$7,163
Ursodiol45$5,631
CholestyramineCholestyramine (With Sugar)75$5,602
Famotidine395$5,523
Pantoprazole Sodium366$4,551
Sucralfate52$4,448
Entecavir14$2,795
Balsalazide Disodium11$2,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,270$153,331105 claims
Aimmune Therapeutics, Inc.Zenpep$20$22,13914 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$166$9,64111 claims
Redhill Biopharma Inc.Movantik$104$7,16317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Shenandoah

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →